MedPath

Integrative Approach to Identify Environmental Risk Factors for CC-17 Group B Streptococcal Neonatal Infection

Not Applicable
Completed
Conditions
Vaginal Colonization With GBS
Interventions
Biological: Bacteriological analyses on clinical samples performed with Eswabs
Registration Number
NCT02471937
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

Streptococcus agalactiae (GBS) is the leading cause of neonatal septicaemia, meningitis, and pneumonia in the industrialized world. Early onset (EOD) and late onset (LOD) diseases are defined in neonates by their occurring within or after the first week of life, respectively. Molecular epidemiological studies have identified a capsular serotype III clone, referred to as CC-17 by Multi Locus Sequence Typing, as accounting for the vast majority of neonatal invasive diseases and for almost all cases of meningitis in LOD.

The investigators working hypothesis is that host-environmental interactions may contribute to the colonization and persistence of the hypervirulent CC-17 GBS in the neonate. In this project the investigators will determine if reciprocal interactions between the intestinal microbiota and the innate and adaptive immune system may specifically facilitate the colonization of the neonate by the hypervirulent GBS CC-17 clone.

Detailed Description

Four specific tasks will be addressed to:

(i) Understand whether and how the gut microbiota may influence growth and colonization of GBS CC-17 within the intestine of neonates.

(ii) Study the contribution of different diets and immune system constituents enabling the persistence of GBS CC-17 in the gut of neonates.

(iii) Determine whether the adaptive immune response elicited by maternal GBS colonization and transmitted to the infant is different for GBS CC-17 versus non-CC-17 GBS.

(iv) Determine whether or not GBS strains isolated from the mothers and from their babies are identical and whether the environment (ie. the vagina or the milk for the mother, the intestine or the oral cavity for the baby) influence the expression of specific virulence factors of CC-17.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
151
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Pregnant women negative for GBS colonizationBacteriological analyses on clinical samples performed with EswabsOnly women negative for GBS during all the study will be included.
Primary Outcome Measures
NameTimeMethod
Number of Negative GBS screening in vaginal samples2 months
Secondary Outcome Measures
NameTimeMethod
Number of Negative GBS screening in fecal samples .at birth
Number of Negative GBS screening in vaginal samplesAt delivery

Trial Locations

Locations (1)

CH Louis Mourier

🇫🇷

Colombes, France

© Copyright 2025. All Rights Reserved by MedPath